Conclusions
In summary, in this national, multicenter, contemporary “real life” setting, we did not observe any change in the rate of VTA. Nevertheless, any VTA following AMI was associated with high short and long-term mortality rate. However, over the past decade there has been a significant improvement in survival rates, especially in patients with late VTA that may be attributed to early and invasive reperfusion therapy, implantable cardioverter defibrillator implantation and better medical treatment.
This statement is to certify that all authors have seen and approved the manuscript
being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the International Journal of Clinical Practice.
The article is the Authors’ original work, has not received prior publication and is not under consideration for publication elsewhere.
All the authors report no relationships that could be construed as a conflict of interest.
References:
1. Metha RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention, JAMA 2009, vol.301 (pg.1779-1789).
2. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes, Circulation 2002, vol. 106 (pg.309-312)
3. Liang JJ, Hodge DO, Metha RA, Russo AM, Prasad A, Cha YM. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48h of acute myocardial infarction: when is ICD appropriate? Europace 2014; 16:1759-66
4. Volpi A, Cavalli A, Santoro E, Tognoni G. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction. Evidence for a protective effect of thrombolytic therapy. GISSI Investigators. Circulation 1990; 82:1279-88
5. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-2165.
6. Asher E, Abu-Much A, Goldenberg I, et al. Platelets and Thrombosis in Sheba-PLATIS Study Group. Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS One 2016;11(6):e0157437
7. Metha RH, Yu J, Piccini JP, et al. Prognostic significance of postprocedual sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol 2012;109(6):805-12
8. Demirel F, Rasoulm S, Elvan A, et al. Impact of out-of-hospital cardiac arrest due to ventricular fibrillation in patients with ST- elevation myocardial infarction admitted for primary percutaneous coronary intervention: Impact of ventricular fibrillation in STEMI patients. Eur Heart J Acute Cardiovasc Care 2015;4(1):16-23.
9. Tofler GH, Stone PH, Muller JE, et al. Prognosis after cardiac arrest due to ventricular tachycardia or ventricular fibrillation associated with acute myocardial infarction (MILIS Study). Multicenter investigation of the limitation of infarct size. Am J Cardiol 1987; 60(10):755-61
10. Metha RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009; 301(17):1779-89.
11. Piccini JP, Berger JS, Brown DL. Early sustained ventricular arrhythmias complicating acute myocardial infarction. Am J Med 2008; 121(9):797-804.
12. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A. Sustained ventricular
arrhythmias in patients receiving thrombolytic therapy: incidence and outcome. The GUSTO investigators. Circulation 1998; 98(23):2567–73.
13. Bulent Gorenek, Carina Blomström Lundqvist, Josep Brugada Terradellas, et al. ESC Scientific Document Group. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force.
EP Europace 2014; 16(11):1655–1673.
14. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 2014;129(14):1483-92.
15. Asher E, Tal S, Mazin I, et al. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol 2017;2(12):1380-1384.
16. Asher E, Frydman S, Katz M, et al. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group. Thromb Haemost 2017;117(4):727-733
17. Asher E, Fefer P, Sabbag A, et al. Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. Thromb Haemost 2016; 115 (2):433–8.
Table 1: Baseline characteristics by VTA presence